Plain-English translation of NCT05242965 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new cancer vaccine called STEMVAC in patients with advanced lung cancer (stage IV non-small cell lung cancer). Half of the participants will receive STEMVAC along with a booster medication, while the other half will receive only the booster medication. The study wants to see if this medication can help your immune system fight the cancer more effectively.
Standard chemotherapy and immunotherapy help some patients, but many still experience cancer growth or return. Researchers believe that teaching your immune system to recognize and attack cancer cells more directly—using a vaccine approach—might offer better long-term outcomes for people in your situation.
You likely qualify if…
You likely don't qualify if…
You will visit the clinic on day 14 of each 21-day cycle to receive injections of either the vaccine plus booster medication (Arm I) or booster medication alone (Arm II). You'll receive 3 doses of injections spaced 3 weeks apart, followed by a booster dose 9 weeks later. During the study, you'll undergo CT scans and have biopsies taken to measure how well the treatment is working, plus regular blood tests. After your treatment ends, you'll have follow-up visits twice yearly for up to 5 years.
AI-generated summary from trial data · Aug 1, 2026 · Not medical advice
United States